The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group – Oral Session (NO001 – NO010)

Cannici, Chiara; Serra, Nicola; Cecco, Valentina De; Lupo, Roberto; Rostagno, Elena; Cioce, Marco; Gargiulo, Gianpaolo; Galgano, Letizia; Caime, Alessandro; Orlando, Laura; Samarani, E.; Botti, Stefano

doi:10.1038/s41409-021-01344-4

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, QoL is affected by various factors during HSCT, and the assessment of its relationship with OM can be very complex [25]. The increase in the degree of OM has been associated with worse patient QoL; the adoption of strategies to prevent OM, such as low-level laser therapy (LLLT) and professional oral care, has led to improvements in QoL [11,26].…”

Section: Introductionmentioning

confidence: 99%

Stem cell transplantation patients receiving a novel oral care protocol for oral mucositis prevention and treatment: patient-reported outcomes and quality of life

Guberti

Botti

Fusco

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

Background Oral mucositis (OM) is one of the most debilitating effects of toxicity due to hematopoietic stem cell transplantation (HSCT) conditioning regimens. The aim of this secondary analysis of the data of a phase II study designed to assess the efficacy of a novel oral care protocol containing bovine colostrum and aloe vera to prevent oral mucositis was to compare outcomes reported by patients with those collected by healthcare professionals (HCPs). Method Data on oral mucositis severity, duration, time of onset and related pain were collected from patients using the Oral Mucositis Daily Questionnaire (OMDQ). HCPs assessed the same outcomes using the World Health Organization oral mucositis scale and pain numerical rating scale. Quality of life was assessed with the 3-level EuroQol-5 dimensions. Results Fifty-nine autologous/allogeneic graft patients were recruited, 46 of whom (78.0%) experienced OM. Mean onset was 9.1 (SD ± 3.5) days after conditioning initiation, mean duration was 10.4 (SD ± 4.3) days, and the average maximum pain score was 3.7 (SD ± 2.7). Self-administration of the OMDQ detected oral symptoms at least 1 day sooner compared to objective assessments (p = 0.025). Significant differences were observed between the patient-reported and the HCP-assessment data on oral mucositis severity grading distribution (p < 0.0001) and highest pain score (p < 0.0001). Quality of life score variations were correlated with changes in oral mucositis severity during patients’ hospital stay. Conclusions Further studies are necessary to improve the understanding of these findings; a randomised controlled trial is being set up at our institution.

show abstract

Section: Introductionmentioning

confidence: 99%

Stem cell transplantation patients receiving a novel oral care protocol for oral mucositis prevention and treatment: patient-reported outcomes and quality of life

Guberti

Botti

Fusco

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…This paper reports the secondary ndings of a phase II study on the e cacy of an experimental BC-AVbased oral care protocol to prevent and treat OM in patients undergoing HSCT (autologous or allogeneic grafts). A rst work compared this experimental approach with a historical control group [27]. The study collected OM-related PROMs in addition to HCP-ROs.…”

Section: Discussionmentioning

confidence: 99%

“…A recent phase II study conducted by our group demonstrated that a BC-AV-based oral care protocol effectively and safely reduced the incidence of severe OM (sOM) in patients undergoing HSCT [27]. In that study, both PROMs and healthcare professional-reported outcomes (HCP-ROs) were collected to give a true picture of toxicity and its effect on QoL.…”

Section: Introductionmentioning

confidence: 99%

Stem Cell Transplantation Patients Receiving a Novel Oral Care Protocol for Oral Mucositis Prevention and Treatment: Patient-reported Outcomes and Quality of Life

Guberti

Botti

Fusco

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Oral mucositis (OM) is one of the most debilitating effects of toxicity due to hematopoietic stem cell transplantation (HSCT) conditioning regimens. The aim of this secondary analysis of the data of a phase II study designed to assess the efficacy of a novel oral care protocol containing bovine colostrum and aloe vera to prevent oral mucositis was to compare outcomes reported by patients with those collected by healthcare professionals (HCPs). Method: Data on oral mucositis severity, duration, time of onset and related pain were collected from patients using the Oral Mucositis Daily Questionnaire (OMDQ). HCPs assessed the same outcomes using the World Health Organization oral mucositis scale and pain numerical rating scale. Quality of life was assessed with the 3-level EuroQol-5 dimensions.Results: Fifty-nine autologous/ allogeneic graft patients were recruited, 46 of whom (78.0%) experienced OM. Mean onset was 9.1 (SD±3.5) days after conditioning initiation, mean duration was 10.4 (SD±4.3) days and the average maximum pain score was 3.7 (SD±2.7). Self-administration of the OMDQ detected oral symptoms at least 1 day sooner compared to objective assessments (p = 0.025). Significant differences were observed between the patient-reported and the HCP-assessment data on oral mucositis severity grading distribution (p < 0.0001) and highest pain score (p < 0.0001). Quality of life score variations were correlated with changes in oral mucositis severity during patients’ hospital stay. Conclusions: Further studies are necessary to improve the understanding of these findings; a randomized controlled trial is being set up at our institution.

show abstract

The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group – Oral Session (NO001 – NO010)

Cited by 2 publications

References 0 publications

Stem cell transplantation patients receiving a novel oral care protocol for oral mucositis prevention and treatment: patient-reported outcomes and quality of life

Stem cell transplantation patients receiving a novel oral care protocol for oral mucositis prevention and treatment: patient-reported outcomes and quality of life

Stem Cell Transplantation Patients Receiving a Novel Oral Care Protocol for Oral Mucositis Prevention and Treatment: Patient-reported Outcomes and Quality of Life

Contact Info

Product

Resources

About